Clinical trial
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in…
NCT00292253 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00292253 |
|---|---|
| Title | Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects |
| Official title | A Randomized, Multicenter, Parallel Group, Open-label Study Comparing the Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing Remitting MS Patients |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Merck Serono International SA Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-remitting |
| Intervention type | Device |
| Interventions | Rebif® via Rebiject™Mini, Rebif® via manual injections |
| Enrollment | 1,883 |
| Start date | Jan 1, 2001 |
| Primary completion | Dec 1, 2002 |
| Completion | Dec 1, 2002 |
| First posted | Feb 15, 2006 |
| Last update posted | Aug 6, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: